tradmap

AEON Earnings AEON Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$627 -$277 $73 $0 2022 2023 2023 2024 2025
EPS
Net income (annual)
-$53M -$5M $42M $0 2021 2022 2024 2025
Net income
Return on equity (annual)
-147% -38% 71% 0% 2021 2022 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$228 -$70 $87 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$298M -$67M $164M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-587% -178% 232% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–17 of 17
Q2 20262026-06-30-0.282026-08-1210-Q
Q1 20262026-03-31-0.292026-05-1410-Q
FY 20252025-12-31-3.952026-03-3010-K
Q3 20252025-09-30-0.232025-11-1410-Q
Q2 20262025-06-300.312026-08-1210-Q
Q1 20262025-03-312.282026-05-1410-Q
FY 20252024-12-3172.932026-03-3010-K
Q3 20252024-09-3069.532025-11-1410-Q
Q2 20252024-06-3087.152025-08-1210-Q
Q1 20252024-03-31-227.872025-05-1410-Q
FY 20242023-12-31-627.332025-03-2410-K
Q3 20242023-09-30-8.012024-11-1310-Q
FY 20242023-07-21-0.442025-03-2410-K
Q2 20242023-06-30-0.242024-08-1210-Q
Q1 20242023-03-31-0.132024-05-1410-Q
FY 20232022-12-31-0.382024-03-2910-K
Q3 20232022-09-30-0.132023-11-1310-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.